Monoclonal IgG4/2. Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation (vol 1, pg 139, 2019)

被引：0
|
作者：
Singh, P.
机构：
来源：
KIDNEY MEDICINE | 2020年 / 2卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：94 / 94
页数：1
相关论文
共 9 条
  • [1] Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation
    Singh, Priyamvada
    Chen, Hui
    Gordon, Craig E.
    Ghai, Sandeep
    Sloan, J. Mark
    Quillen, Karen
    Moradi, Sara
    Chitalia, Vipul
    Gautam, Amitabh
    Henderson, Joel
    Francis, Jean M.
    KIDNEY MEDICINE, 2019, 1 (03) : 139 - 143
  • [2] Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation
    Duineveld, Caroline
    Bouwmeester, Romy N.
    Wijnsma, Kioa L.
    Bemelman, F. J.
    van der Heijden, J. W.
    Berger, S. P.
    van den Heuvel, L. P. W. J.
    van de Kar, Nicole C. A. J.
    Wetzels, Jack F. M.
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (04): : 715 - 726
  • [3] PREEMPTIVE PLASMA THERAPY AND ECULIZUMAB RESCUE FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME RELAPSE FOLLOWING KIDNEY TRANSPLANTATION
    Aigner, Christof
    Boehmig, Georg
    Eskandary, Farsad
    Gaggl, Martina
    Kain, Renate
    Sunder-Plassmann, Raute
    Prohaszka, Zoltan
    Schmidt, Alice
    Sunder-Plassmann, Gere
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [4] Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use (vol 33, pg 1, 2019)
    Wijnsma, Kioa L.
    Duineveld, Caroline
    Wetzels, Jack F. M.
    van de Kar, Nicole C. A. J.
    PEDIATRIC NEPHROLOGY, 2019, 34 (04) : 741 - 742
  • [5] SUCCESSFUL TREATMENT OF RECURRENT ATYPICAL HEMOLYTIC-UREMIC SYNDROME WITH ECULIZUMAB AFTER PEDIATRIC KIDNEY TRANSPLANTATION
    Somers, Michael J. G.
    Rodig, Nancy M.
    PEDIATRIC TRANSPLANTATION, 2011, 15 : 82 - 82
  • [6] TERMINAL COMPLEMENT BLOCKADE BY ECULIZUMAB EFFECTIVELY REVERSES RECURRENT ATYPICAL HEMOLYTIC UREMIC SYNDROME AFTER KIDNEY TRANSPLANTATION
    Heyne, N.
    Weitz, M.
    Guthoff, M.
    Alscher, M. D.
    Haering, H. -U.
    Koenigsrainer, A.
    Nadalin, S.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 35 - 35
  • [7] Preemptive Plasma Therapy and Eculizumab (ECU) Rescue for Atypical Hemolytic Uremic Syndrome (aHUS) Relapse Following Kidney Transplantation (KTX).
    Aigner, C.
    Boehmig, G.
    Eskandary, F.
    Gaggl, M.
    Kain, R.
    Sunder-Plassmann, R.
    Prohaszka, Z.
    Schmidt, A.
    Sunder-Plassmann, G.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 793 - 794
  • [8] PREVENTIVE PLASMA THERAPY FOR PREVENTION OF ATYPICAL HEMOLYTIC UREMIC SYNDROME RELAPSE FOLLOWING KIDNEY TRANSPLANTATION
    Aigner, Christof
    Boehmig, Georg A.
    Eskandary, Farsad
    Herkner, Harald
    Prohaszka, Zoltan
    Kain, Renate
    Gaggl, Martina
    Sunder-Plassmann, Raute
    Mueller-Sacherer, Thomas
    Oszwald, Andre
    Fischer, Gottfried
    Alice, Schmidt
    Gere, Sunder-Plassmann
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 364 - 364
  • [9] Kidney outcome following 12 weeks of eculizumab therapy for atypical hemolytic uremic syndrome. Results of a national cohort of 98 children during 2018-2023
    Skibiak, Aleksandra
    Zagozdzon, Ilona
    Zurowska, Aleksandra
    Panczyk-Tomaszewska, Malgorzata
    Grenda, Ryszard
    Zwolinska, Danuta
    Zachwieja, Jacek
    Szczepanska, Maria
    Wasilewska, Anna
    Tkaczyk, Marcin
    Drozdz, Dorota
    PEDIATRIC NEPHROLOGY, 2024, 39 (01) : S111 - S111
1